By Iacob Pastina · Independent Editor
Medicare GLP-1 Coverage: Everything Changing in July 2026
Medicare will begin covering GLP-1 weight loss medications at $50/month starting July 2026. Here's who qualifies, how it works, and what comes next.
On Medicare? Here's the path
Coverage starts July 1, 2026 — $50/mo for Wegovy, Zepbound & Foundayo
The Medicare GLP-1 Bridge program brings four FDA-approved drugs to a flat $50/mo copay for eligible Part D beneficiaries. Until then, no telehealth provider on this site works directly with Medicare for GLP-1 weight loss — the Bridge is the path, not a third-party prescriber.
Read first
Medicare GLP-1 Bridge enrollment guide →
What's covered, who qualifies, how prior auth works.
Then check
Am I eligible? — 60-second checker →
BMI, comorbidities, current Part D plan — instant readout.
Providers ready for the Bridge
These three already prescribe the FDA-approved drugs the Bridge will cover — their workflows plug straight into Part D prior auth. Picked from the affiliate-eligible top of our rankings, not paid placement.
Summarize this article with
Medicare will cover Wegovy and Zepbound for weight loss at a flat $50/month copay starting July 2026, through the Medicare GLP-1 Bridge Demonstration program. Approximately 3.4 million Medicare beneficiaries are expected to qualify. The Medicare GLP-1 Bridge Demonstration, announced by CMS on December 23, 2025, represents the first time Medicare has covered weight loss drugs since Part D began in 2006. Use our insurance coverage lookup to check your specific plan, or compare all 48 providers to find one that accepts Medicare.
What Does the Medicare GLP-1 Bridge Program Cover?
- •Launch date: July 2026
- •Your cost: $50/month copayment
- •Medications covered: Wegovy (semaglutide) and Zepbound (tirzepatide)
- •Negotiated manufacturer price: $245/month (paid by the program)
- •Who qualifies: Medicare Part D enrollees meeting BMI and related health condition criteria
- •Estimated eligible population: ~10% of Medicare beneficiaries
This is a significant shift. Until now, Medicare Part D explicitly excluded weight loss drugs. Coverage was only available for GLP-1s prescribed for Type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea — not weight management alone.
Every Tuesday. One email. The cheapest verified GLP-1 programs of the week.
Price drops, FDA alerts, new programs ranked, and compounded shortages — delivered Tuesday morning. No filler. Unsubscribe anytime.
No affiliate spam. No retargeting pixels. Unsubscribe in one click.
How Does Medicare GLP-1 Pricing Work?
The pricing structure came from a Most-Favored-Nation deal between the Trump administration and both Novo Nordisk and Eli Lilly. Both manufacturers agreed to a net price of $245/month — roughly 75-80% below the retail list price.
For context, Wegovy lists at approximately $1,349/month and Zepbound at about $1,086/month. The $245 negotiated price represents the lowest official price point for brand-name GLP-1s anywhere in the US system.
Additionally, the Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap (effective since 2025) provides a backstop — even if you use other medications, your total annual prescription spending is capped.
Not sure which GLP-1 program is right for you?
Take the 60-second quiz — we'll match you against 48 verified providers on your goals, budget, and medication preference, then surface your top 3.
Take the 60-sec QuizWho Qualifies for Medicare GLP-1 Coverage?
To qualify for the Medicare GLP-1 Bridge, you'll need:
- •Active Medicare Part D enrollment
- •BMI of 30 or higher, OR BMI of 27+ with at least one weight-related condition
- •Related health conditions may include Type 2 diabetes, hypertension, cardiovascular disease, sleep apnea, and others
- •Prescription from a qualifying provider
Specific enrollment details and participating pharmacies are expected to be announced by CMS in the months leading up to the July launch.
What Comes After: The BALANCE Model
The Bridge program is temporary — designed to provide immediate access while the larger BALANCE Model rolls out. BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is a voluntary CMS demonstration that combines GLP-1 coverage with lifestyle supports.
- •Medicare Part D plans can participate starting January 2027
- •State Medicaid agencies can opt in starting May 2026
- •CMS will negotiate drug pricing on behalf of all participating plans and states
- •The program includes behavioral health, nutrition counseling, and other lifestyle components alongside medication
What to Do Now
If you're on Medicare and interested in GLP-1 treatment for weight loss, here's what you can do before July 2026:
- •Talk to your doctor about whether you're a candidate based on BMI and health conditions
- •Ensure your Medicare Part D plan is active and current
- •If you have a diabetes diagnosis, your doctor may already be able to prescribe GLP-1s under existing coverage
- •Watch for CMS announcements about specific enrollment procedures as July approaches
- •Check if your current Part D plan has announced participation in the BALANCE Model for 2027
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any medication. Information is current as of the publication date but may change.
Affiliate Disclosure: Some links in this article are affiliate links. We may earn a commission if you sign up through our links, at no extra cost to you.
Check Your Medicare Eligibility
$50/mo copay for Wegovy, Zepbound, Wegovy oral, and Foundayo starts July 1, 2026 via the Medicare GLP-1 Bridge.